{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:31:51Z","timestamp":1791498711553,"version":"4.3.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Funded by Genmab A\/S and AbbVie"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41375-024-02410-8","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T16:42:19Z","timestamp":1727282539000},"page":"2653-2662","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":153,"title":["Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9941-2448","authenticated-orcid":false,"given":"Catherine","family":"Thieblemont","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin H.","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Ghesquieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Y.","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Roost","family":"Clausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1879-8084","authenticated-orcid":false,"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Rok","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1225-8757","authenticated-orcid":false,"given":"Robin","family":"Gasiorowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David John","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6145-4426","authenticated-orcid":false,"given":"Tae Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"van der Poel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Limei","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim M.","family":"Linton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1238-6970","authenticated-orcid":false,"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hutchings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6505-8877","authenticated-orcid":false,"given":"Minh H.","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurgul","family":"Kilavuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Soong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Sacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tycel","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieternella J.","family":"Lugtenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,25]]},"reference":[{"key":"2410_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"2410_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/hon.2847","volume":"39","author":"K Wienand","year":"2021","unstructured":"Wienand K, Chapuy B. Molecular classification of aggressive lymphomas-past, present, future. Hematol Oncol. 2021;39:24\u201330.","journal-title":"Hematol Oncol"},{"key":"2410_CR3","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384:842\u201358.","journal-title":"N Engl J Med"},{"key":"2410_CR4","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","volume":"32","author":"MJ Maurer","year":"2014","unstructured":"Maurer MJ, Ghesqui\u00e8res H, Jais JP, Witzig TE, Haioun C, Thompson CA, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32:1066\u201373.","journal-title":"J Clin Oncol"},{"key":"2410_CR5","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1200\/JCO.2016.70.0765","volume":"35","author":"LH Jakobsen","year":"2017","unstructured":"Jakobsen LH, B\u00f8gsted M, Brown PN, Arboe B, J\u00f8rgensen J, Larsen TS, et al. Minimal loss of lifetime for patients with diffuse large B-cell lymphoma in remission and event free 24 months after treatment: a Danish population-based study. J Clin Oncol. 2017;35:778\u201384.","journal-title":"J Clin Oncol"},{"key":"2410_CR6","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800\u20138.","journal-title":"Blood"},{"key":"2410_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45\u201356.","journal-title":"N Engl J Med"},{"key":"2410_CR8","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"Abramson","year":"2020","unstructured":"Abramson, Palomba JS, Gordon LI ML, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839\u201352.","journal-title":"Lancet"},{"key":"2410_CR9","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"2410_CR10","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J Clin Oncol. 2023;41:2238\u201347.","journal-title":"J Clin Oncol"},{"key":"2410_CR11","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387:2220\u201331.","journal-title":"N Engl J Med"},{"key":"2410_CR12","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22:1403\u201315.","journal-title":"Lancet Oncol"},{"key":"2410_CR13","first-page":"2307","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141:2307\u201315.","journal-title":"Blood"},{"key":"2410_CR14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"key":"2410_CR15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","volume":"402","author":"N van de Donk","year":"2023","unstructured":"van de Donk N, Zweegman S. T-cell-engaging bispecific antibodies in cancer. Lancet. 2023;402:142\u201358.","journal-title":"Lancet"},{"key":"2410_CR16","doi-asserted-by":"publisher","first-page":"e002056","DOI":"10.1136\/jitc-2020-002056","volume":"9","author":"GD Myers","year":"2021","unstructured":"Myers GD, Verneris MR, Goy A, Maziarz RT. Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia. J Immunother Cancer. 2021;9:e002056.","journal-title":"J Immunother Cancer"},{"key":"2410_CR17","unstructured":"Epkinly [package insert]. Plainsboro, NJ, USA: Genmab US, Inc.; 2024."},{"key":"2410_CR18","unstructured":"Tepkinly [summary of product characteristics]. Ludwigshafen, Germany: AbbVie Deutschland GmbH & Co. KG; 2023."},{"key":"2410_CR19","unstructured":"Epkinly [Japan package insert]. Minato-Ku, Tokyo, Japan: AbbVie GK, Genmab K.K.; 2023."},{"key":"2410_CR20","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: B-cell lymphomas v1. 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/default_nojava.aspx."},{"key":"2410_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.102625","volume":"52","author":"PJ Engelberts","year":"2020","unstructured":"Engelberts PJ, Hiemstra IH, de Jong B, Schuurhuis DH, Meesters J, Beltran Hernandez I, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020;52:102625.","journal-title":"EBioMedicine"},{"key":"2410_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00430-6","volume":"11","author":"HJ van der Horst","year":"2021","unstructured":"van der Horst HJ, de Jonge AV, Hiemstra IH, Gelderloos AT, Berry DRAI, Hijmering NJ, et al. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer J. 2021;11:38.","journal-title":"Blood Cancer J"},{"key":"2410_CR23","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","volume":"398","author":"M Hutchings","year":"2021","unstructured":"Hutchings M, Mous R, Clausen MR, Johnson P, Linton KM, Chamuleau MED, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study. Lancet. 2021;398:1157\u201369.","journal-title":"Lancet"},{"key":"2410_CR24","doi-asserted-by":"crossref","unstructured":"Vose JM, Feldman T, Chamuleau MED, Kim WS, Lugtenburg P, Kim TM, et al. Mitigating the risk of cytokine release syndrome (CRS): preliminary results from a DLBCL cohort of EPCORE NHL-1 [poster 1729]. Annual Meeting and Exposition of the American Society of Hematology; 9\u201312 December 2023; San Diego, CA.","DOI":"10.1182\/blood-2023-180333"},{"key":"2410_CR25","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"2410_CR26","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.clml.2020.12.013","volume":"21","author":"SD Smith","year":"2021","unstructured":"Smith SD, Lopedote P, Samara Y, Mei M, Herrera AF, Winter AM, et al. Polatuzumab vedotin for relapsed\/refractory aggressive B-cell lymphoma: a multicenter post-marketing analysis. Clin Lymphoma Myeloma Leuk. 2021;21:170\u20135.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2410_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","volume":"38","author":"LH Sehn","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38:155\u201365.","journal-title":"J Clin Oncol"},{"key":"2410_CR28","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","volume":"21","author":"G Salles","year":"2020","unstructured":"Salles G, Duell J, Gonz\u00e1lez Barca E, Tournilhac O, Jurczak W, Liberati AM, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21:978\u201388.","journal-title":"Lancet Oncol"},{"key":"2410_CR29","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","volume":"7","author":"N Kalakonda","year":"2020","unstructured":"Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020;7:e511\u2013e522.","journal-title":"Lancet Haematol"},{"key":"2410_CR30","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","volume":"22","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22:790\u2013800.","journal-title":"Lancet Oncol"},{"key":"2410_CR31","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1158\/1078-0432.CCR-21-3648","volume":"28","author":"GS Nowakowski","year":"2022","unstructured":"Nowakowski GS, Yoon DH, Peters A, Mondello P, Joffe E, Fleury I, et al. Improved efficacy of tafasitamab plus lenalidomide versus systemic therapies for relapsed\/refractory DLBCL: RE-MIND2, an observational retrospective matched cohort study. Clin Cancer Res. 2022;28:4003\u201317.","journal-title":"Clin Cancer Res"},{"key":"2410_CR32","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1182\/blood.2022016945","volume":"140","author":"R Di Blasi","year":"2022","unstructured":"Di Blasi R, Le Gouill S, Bachy E, Cartron G, Beauvais D, Le Bras F, et al. Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis. Blood. 2022;140:2584\u201393.","journal-title":"Blood"},{"key":"2410_CR33","doi-asserted-by":"crossref","unstructured":"Ayyappan S, Kim WS, Kim TM, Walewski J, Cho S-G, Jarque I, et al. Final analysis of the phase 2 ELM-2 study: odronextamab in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL). Annual Meeting of the American Society of Hematology; 9\u201312 December 2023; San Diego, CA.","DOI":"10.1182\/blood-2023-179818"},{"key":"2410_CR34","doi-asserted-by":"crossref","unstructured":"Hutchings M, Stella CC, Morschhauser F, Falchi L, Bachy E, Cartron G, et al. Glofitamab monotherapy in relapsed or refractory large B cell lymphoma: Extended follow up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T cell therapy and by baseline total metabolic tumor volume [oral presentation]. Annual Meeting and Exposition of the American Society of Hematology; 9\u201312 December 2023; San Diego, CA.","DOI":"10.1182\/blood-2023-173951"},{"key":"2410_CR35","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s10787-023-01253-6","volume":"31","author":"M Sabbatucci","year":"2023","unstructured":"Sabbatucci M, Vitiello A, Clemente S, Zovi A, Boccellino M, Ferrara F, et al. Omicron variant evolution on vaccines and monoclonal antibodies. Inflammopharmacology. 2023;31:1779\u201388.","journal-title":"Inflammopharmacology"},{"key":"2410_CR36","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13045-020-00970-7","volume":"13","author":"J Garc\u00eda-Su\u00e1rez","year":"2020","unstructured":"Garc\u00eda-Su\u00e1rez J, de la Cruz J, Cedillo \u00c1, Llamas P, Duarte R, Jim\u00e9nez-Yuste V, et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol. 2020;13:133.","journal-title":"J Hematol Oncol"},{"key":"2410_CR37","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s10238-023-01004-5","volume":"23","author":"N Hardy","year":"2023","unstructured":"Hardy N, Vegivinti CTR, Mehta M, Thurnham J, Mebane A, Pederson JM, et al. Mortality of COVID-19 in patients with hematological malignancies versus solid tumors: a systematic literature review and meta-analysis. Clin Exp Med. 2023;23:1945\u201359.","journal-title":"Clin Exp Med"},{"key":"2410_CR38","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1182\/blood.2021012251","volume":"140","author":"P Langerbeins","year":"2022","unstructured":"Langerbeins P, Hallek M. COVID-19 in patients with hematologic malignancy. Blood. 2022;140:236\u201352.","journal-title":"Blood"},{"key":"2410_CR39","doi-asserted-by":"publisher","first-page":"324","DOI":"10.4143\/crt.2023.738","volume":"56","author":"CM Lee","year":"2024","unstructured":"Lee CM, Choe PG, Kang CK, Jo HJ, Kim NJ, Yoon SS, et al. Impact of T-cell engagers on COVID-19-related mortality in B-cell lymphoma patients receiving B-cell depleting therapy. Cancer Res Treat. 2024;56:324\u201333.","journal-title":"Cancer Res Treat"},{"key":"2410_CR40","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1007\/s00277-023-05315-1","volume":"102","author":"VR Nachar","year":"2023","unstructured":"Nachar VR, Perissinotti AJ, Marini BL, Karimi YH, Phillips TJ. COVID-19 infection outcomes in patients receiving CD20 targeting T-cell engaging bispecific antibodies for B-cell non-Hodgkin lymphoma. Ann Hematol. 2023;102:2635\u20137.","journal-title":"Ann Hematol"},{"key":"2410_CR41","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1182\/blood-2023-181650","volume":"142","author":"JC Villasboas","year":"2023","unstructured":"Villasboas JC, Kim TM, Taszner M, Novelli S, Cho S-G, Merli M, et al. Results of a second, prespecified analysis of the phase 2 study ELM-2 confirm high rates of durable complete response with odronextamab in patients with relapsed\/refractory (R\/R) follicular lymphoma (FL) with extended follow-up [abstract]. Blood. 2023;142:3041.","journal-title":"Blood"},{"key":"2410_CR42","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/bjh.19156","volume":"204","author":"ER Kyvsgaard","year":"2024","unstructured":"Kyvsgaard ER, Riley C, Clausen MR, Harsl\u00f8f M, Heftdal LD, Niemann CU, et al. Low mortality from COVID-19 infection in patients with B-cell lymphoma after bispecific CD20xCD3 therapy. Br J Haematol. 2024;204:356\u201360.","journal-title":"Br J Haematol"},{"key":"2410_CR43","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1182\/blood-2022-169321","volume":"140","author":"M Jim\u00e9nez","year":"2022","unstructured":"Jim\u00e9nez M, Novoa J\u00e1uregui S, Fern\u00e1ndez-Naval C, Bosch Schips M, Muzio S, Navarro Garc\u00e9s V, et al. Clinical impact of Sars-Cov-2 vaccination in COVID-19 outcomes in patients diagnosed with hematologic malignancies: real-world evidence of two years of pandemic [abstract]. Blood. 2022;140:2628\u201330.","journal-title":"Blood"},{"key":"2410_CR44","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia. 2022;36:1720\u201348.","journal-title":"Leukemia"},{"key":"2410_CR45","doi-asserted-by":"crossref","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25:625\u201338.","DOI":"10.1016\/j.bbmt.2018.12.758"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02410-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02410-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02410-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T06:03:39Z","timestamp":1732514619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02410-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,25]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2410"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02410-8","relation":{"is-basis-for":[{"id-type":"doi","id":"10.52843\/cassyni.wrv20r","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,25]]},"assertion":[{"value":"26 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CT reports research funding from BMS, Hospira, and Roche; consulting role for AbbVie, Amgen, BMS, Cellectis, Gilead Sciences, Kite, Novartis, and Roche; honoraria from AbbVie, Amgen, Bayer, Cellectis, Gilead Sciences, Incyte, Janssen, Kite, Novartis, and Takeda; membership on an entity\u2019s board of directors or advisory committees at AbbVie, Amgen, BMS, Cellectis, Gilead Sciences, Incyte, Janssen, Kite, Novartis, Roche, and Takeda; and travel expenses from AbbVie, Amgen, BMS, Cellectis, Gilead Sciences, Kite, Novartis, and Roche. YHK reports consulting\/advisory role for AbbVie and ADC Therapeutics; travel expenses from Roche\/Genentech; and research funding from AbbVie, AstraZeneca, Lilly\/Loxo, Merck, Roche\/Genentech, and Xencor. HG reports consulting role for Gilead and Roche; and honoraria from AbbVie, BMS, Gilead, and Roche. CYC reports consulting\/advisory roles and honoraria from Roche, Janssen, Gilead, AstraZeneca, Lilly, BeiGene, Menarini, Dizal, AbbVie, Genmab, Sobi, BMS, and Regeneron; research funding from BMS, Roche, AbbVie, MSD, and Lilly; speakers bureau for Janssen, AstraZeneca, BeiGene, Genmab, AbbVie, and Roche; and travel expenses from Lilly and BeiGene. MRC reports consulting role for AbbVie, Janssen, Gilead, AstraZeneca, Genmab, and Incyte; advisory role for AbbVie, Janssen, Gilead, and Genmab; and travel expenses from AbbVie, Janssen, AstraZeneca, Genmab, Roche, and Pfizer. DC reports research grants (paid to institution, Royal Marsden Hospital) from MedImmune\/AstraZeneca, Clovis, Lilly, 4SC, Bayer, BMS, and Roche. WJ reports research funding and consulting role for AbbVie and Roche. YRD reports no conflicts of interest. RG reports honoraria from MSD, Otsuka, Novartis, Astellas, Janssen, AbbVie, and Takeda. DJL reports consulting\/advisory role for Janssen, Lilly, Roche, BeiGene, and Kite. TMK reports consulting for Amgen, AstraZeneca\/MedImmune, Boryung, Daiichi Sankyo, F. Hoffmann-La Roche Ltd\/Genentech, HK inno.N, Janssen, Novartis, Regeneron, Samsung Bioepis, Takeda, and Yuhan; honoraria from Amgen, AstraZeneca\/MedImmune, IMBdx, Janssen, and Takeda; and membership on an entity\u2019s board of directors or advisory committees at Amgen, BeiGene, Janssen, Novartis, Regeneron, Samsung Bioepis, and Takeda. MvdP reports no conflicts of interest. MLP reports no conflicts of interest. TF reports consulting role for AbbVie, AstraZeneca, Epizyme, Genmab, Gilead\/Kite, Karyopharm, and Takeda; and consulting role\/speakers bureau for Seagen. KML reports membership on the Epcoritamab Global Council for Genmab; consulting\/advisory role for AbbVie, BeiGene, BMS, Genmab, Kite\/Gilead, and Roche; speakers bureau for AbbVie and BMS; research funding (paid to institution) from AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, BMS, CellCentric, Genmab, Janssen, Kite\/Gilead, MorphoSys, MSD, Nurix, Regeneron, Roche, Step Pharma, and Viracta; and travel expenses from BMS. AS reports consulting role for Takeda, BMS, Novartis, Janssen, MSD, Amgen, GSK, Sanofi, Kite, and Mundipharma; honoraria from Takeda, BMS, Novartis, Janssen, MSD, Amgen, GSK, Sanofi, and Kite; membership on an entity\u2019s board of directors or advisory committees for Takeda, BMS, Novartis, Janssen, Amgen, Bluebird, Sanofi, and Kite; travel expenses from Takeda, BMS, and Roche; research funding from Takeda; and speakers bureau for Takeda, BMS, Novartis, Janssen, MSD, Amgen, GSK, Sanofi, and Kite. MH reports scientific advisory boards for AbbVie, BMS, Genmab, Janssen, Roche, and Takeda; and research support (paid to institution) from BMS, Genentech, Genmab, Incyte, Janssen, Novartis, Roche, and Takeda. MHD reports employment with AbbVie. NK reports employment with Genmab. DS reports employment with Genmab. TM reports employment with Genmab. MS reports employment with Genmab. TP reports consulting\/advisory role for Pfizer\/Seagen, Pharmacyclics, Incyte, Genentech, Bayer, Gilead Sciences, Curis, Kite\/Gilead, BMS, Genmab, TG Therapeutics, and ADC Therapeutics; honoraria from Pfizer\/Seagen and Lymphoma & Myeloma Connect; research funding from AbbVie, Pharmacyclics\/Janssen, and Bayer; and \u00a0is a scholar in the Clinical Research of The Leukemia & Lymphoma Society. PJL reports research grants from Takeda and Servier; advisory honoraria from BMS, Roche, Takeda, Genmab, AbbVie, Incyte, Regeneron, and Sandoz; and consultancy honoraria from Y-mAbs Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The trial was conducted in accordance with regulatory requirements, International Council for Harmonization Good Clinical Practice Guidelines, and the Declaration of Helsinki. The study protocol was approved by site-specific Institutional Review Boards and\/or Institutional or Central Ethics Committees (Central Ethics Committee: H\u00f4pital Saint-Antoine Comit\u00e9 de Protection des Personnes [CPP] Ile de France V; Paris, France; 2017-001748-36), and all patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}